Novel inhibitors of AP-1 and NF-kappaB mediated gene expression: structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)++ +pyrimidi ne-5-carboxylate.
暂无分享,去创建一个
A. Manning | M. Suto | A M Manning | M. Palanki | P. Erdman | C. Suto | L J Ransone | M S Palanki | P E Erdman | A Ow | C Spooner | C Suto | M Suto | L. Ransone | A. Ow | C. Spooner
[1] A. Manning. Transcription factors: a new frontier for drug discovery , 1996 .
[2] M. Otto,et al. Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating. , 1987, Journal of Medicinal Chemistry.
[3] Rheumatoid arthritis. 1. , 1969 .
[4] D. Powell,et al. New Synthetic Routes to 3-, 5-, and 6-Aryl-2-chloropyridines , 1995 .
[5] D. W. Anderson,et al. 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-kappa B- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry. , 1998, Journal of medicinal chemistry.
[6] A. Manning,et al. Interleukin-2 inhibitors in autoimmune disease , 1999 .
[7] M. Kuhar,et al. Synthesis, Ligand Binding, and Quantitative Structure−Activity Relationship Study of 3β-(4‘-Substituted phenyl)-2β-heterocyclic Tropanes: Evidence for an Electrostatic Interaction at the 2β-Position , 1996 .